ClinicalTrials.gg
CompletedNCT03025438Updated Dec 18, 2017

Cytological Diagnosis of Hepatic Angiosarcoma and Its Histopathologic Correlation

An observational study in Hepatic Angiosarcoma, sponsored by National Taiwan University Hospital. Completed at 1 site in Taiwan. Open to participants aged 20 Years to 100 Years. Per ClinicalTrials.gov, last updated 2017-12-18.

Sponsored by National Taiwan University Hospital · Observational

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
13
Ages
20 Years to 100 Years
Sex
All
01

Study summary

Cytological diagnosis of hepatic angiosarcoma by fine-needle aspiration (FNA) or imprint cytology is difficult due not only to its various cytomorphologic features but also clinical rarity. Vasoformative features, such as pseudo-acini, branching pseudo-capillary structure, and intracytoplasmic lumina, are clues to achieve the diagnosis. But these features are not always present. In order to find clues for cytological diagnosis of angiosarcoma, we collected cases of hepatic angiosarcoma to study their cytological features. And then compared these features with those in their histopathological biopsy or resection.

Read the detailed description

Hepatic angiosarcoma is a rare hepatic malignant tumor. Although diagnosis of hepatic angiosarcoma by FNA cytology has been reported since 1982, followed by several studies, its cytomorphologic features were still not well recognized by cytopathologists because of its clinical rarity and various morphologic features.

We reviewed literatures about cytomorphology of hepatic angiosarcoma by FNA. There are only 11 cases retrieved in 10 articles searched from Medline. The sex M/F ratio was 6/4 (one unknown); age range was 56 to 79 years old. In initial cytological evaluation, four cases got angiosarcoma or consistent/suspicious angiosarcoma diagnosis. Positive for malignancy, sarcoma, and poorly differentiated spindle cell lesion were in one case respectively. One was diagnosed as atypical cells. Remaining three were unavailable by their reports.

In cytological morphologic features, all but one met least 2 of 3 cytological cellular criteria of angiosarcoma cells: spindle cells, epithelioid cells, and pleomorphic cells. In cytological architectural features, 7 of 11 cases showed vasoformative structures; 5 of 11 cases showed intracytoplasmic lumen or erythrophagocytosis. Ten of 11 cases had histologic/pathologic confirmation as angiosarcoma. One case reported interrelation of tumor structures and their own accompanied liver tissue in cell blocks.

02

Conditions studied

  • Hepatic Angiosarcoma

Keywords

  • angiosarcoma
  • Cytology
  • liver
  • cancer
03

In context

Hemangiosarcoma

99 studies on the registry are indexed under Hemangiosarcoma; 16 are open to participants now.

Browse Hemangiosarcoma studies →

Lead sponsor

National Taiwan University Hospital is the lead sponsor of 2,615 studies on the registry; 576 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

patients of a medical center in Taiwan; National Taiwan University Hospital (NTUH)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Consecutive patients of hepatic angiosarcoma performed FNA and/or imprint cytological examinations in our hospital.

Exclusion criteria

Exclusion criteria:

  1. Patients without pathological confirmation.
  2. Patients who are not angiosarcoma by pathological reviews.
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
13 participants (actual)
06

What researchers measure

Primary outcomes

  1. all cause mortality

    Time frame: about 10 years from the date of diagnosis to the last follow-up date by medical record

07

Study locations

1 site
  • National Taiwan University Hospital, Department of laboratory medicine
    Taipei, 10008, Taiwan
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03025438
Responsible party
Sponsor
First posted
Jan 19, 2017
Start date
Jan 17, 2017
Primary completion
Feb 4, 2017
Completion
Apr 3, 2017
Last update
Dec 18, 2017

Study contacts

Wern-Cherng Cheng, MD
principal investigator · National Taiwan University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion